Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04551950 · ClinicalTrials.gov registry record · Phase 1
Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)
A Phase 1 study, sponsored by EMD Serono Research & Development Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT04551950 is a Phase 1 study that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 25 participants.
The verdict
NCT04551950, a Phase 1 study, has completed, sponsored by EMD Serono Research & Development Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study was to evaluate the safety and tolerability of bintrafusp alfa in combination with other anti-cancer therapies in participants with locally advanced or advanced cervical cancer.
Interventions
- DRUG Bevacizumab
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Paclitaxel
- DRUG M7824
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-10-19 |
| Est. Completion | 2022-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04551950
The ClinicalTrials.gov registry entry for NCT04551950 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT04551950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04551950 about?
NCT04551950 is a clinical study titled "Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)". This study was to evaluate the safety and tolerability of bintrafusp alfa in combination with other anti-cancer therapies in participants with locally advanced or advanced cervical cancer.
What is the current status of trial NCT04551950?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2020-10-19. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT04551950?
The interventions under investigation include: Bevacizumab (DRUG), Carboplatin (DRUG), Cisplatin (DRUG), Paclitaxel (DRUG), M7824 (DRUG).
Who is sponsoring clinical trial NCT04551950?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.